CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Nuvation Bio Q3 revenue up on IBTROZI sales 

By Reuters News


Overview

  • Oncology drugmaker's Q3 revenue rose to $45 mln, up from a year earlier

  • Net loss for Q3 narrowed to $41.9 mln from $55.8 mln last year

  • FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma


Outlook

  • Company plans further updates on drug-drug conjugate platform by year-end 2026

  • Nuvation Bio advancing Phase 2 and pivotal Phase 3 studies for safusidenib in IDH1-mutant glioma

  • Company expanding SIGMA Phase 3 study for safusidenib to additional European countries


Result Drivers

  • IBTROZI GROWTH - Net product revenue for IBTROZI rose 18% quarter-over-quarter, driven by continued adoption and treatment durability

  • MARKET LEADERSHIP - IBTROZI maintained its position as the most prescribed ROS1 TKI, with new patient starts steady despite a 15% decline in the overall market

  • COLLABORATION REVENUE - Higher collaboration and license revenue was driven by increased product supply revenue, a sales milestone, and greater royalty income


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.12

Q3 Net Loss

$41.90 mln

Q3 Income from Pperations

-$42.21 mln

Q3 Pretax Loss

$41.90 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Nuvation Bio Inc. is $12.00, about 155.9% above its November 3 closing price of $4.69


Reuters Recommended Reads

  • Nov 4 - BioCryst Q3 revenue rises 13% on ORLADEYO sales

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.